Turn Therapeutics Inc. insider trading
Every open-market purchase and sale by Turn Therapeutics Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Turn Therapeutics Inc.’s insiders pay?
From October 23, 2025 to November 25, 2025, 3 insiders reported 5 open-market purchases and 0 sales not made under a pre-set plan in Turn Therapeutics Inc. Twelve months after each purchase was reported, the shares were +84.1% against the S&P 500 on average (median +90.3%), over 3 purchases with a full year of prices; 100% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on October 24, 2025 into $20,535 by November 2, 2026, +103.0% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $11,281 (+12.6% a year), and held throughout $11,290 (+12.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Golden Arthur F | Director | 3 | +90.3% (1) | 100% | 0 | — | November 25, 2025 |
| Chaudhary Zuraiz | See Remarks | 1 | +90.3% (1) | 100% | 0 | — | October 23, 2025 |
| Chesed Abraham | Other | 1 | +71.7% (1) | 100% | 0 | — | October 29, 2025 |